SeaStar Medical Holding Corporation ICU 深 滬
已收盤 02-06 16:00:00 美东时间
2.48
+0.070
+2.90%
華盛通- 最 高2.52
- 今 開2.42
- 成交量 5.27万股
- 最 低 2.3632
- 昨 收 2.41
- 總市值 942.40万
- 52周最高 25.70
- 市盈率 靜 --
- 換手率 1.39%
- 52周最低 2.20
- 委 比 50.00%
- 總股本 380.00万
- 歷史最高 3050.00
- 量 比 0.58
- 振 幅 6.51%
- 歷史最低 2.20
- 每 手 1
- 風險率 5.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
SeaStar Medical Holding Corporation announced that CEO Eric Schlorff will present at Noble Capital Markets’ conference on February 5th. Interested parties can register for the live presentation or access the replay on February 9th. SeaStar Medical specializes in transforming treatments for critically ill patients, with its QUELIMMUNE therapy approved for life-threatening acute kidney injury in pediatric patients. The company is also conducting p...
01-29 13:25
SeaStar Medical Announces 2026 Milestones
SeaStar Medical outlines 2026 milestones to expand QUELIMMUNE adoption for ultra-rare pediatric AKI, advance the NEUTRALIZE-AKI pivotal trial for adult AKI, and explore broader applicability of its SCD therapy in heart failure patients. The company aims to double its customer base, achieve $2 million in revenue, and leverage FDA designations to accelerate approvals. Recent achievements include successful interim trial results, real-world data val...
01-07 13:13
SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference
SeaStar Medical's CEO, Eric Schlorff, will present at the Biotech Showcase 2026 on January 13, 2026, at 3:00 p.m. PST. The live presentation and replay will be available on the company’s website. Additionally, SeaStar’s management will meet with investors during the J.P. Morgan Healthcare Conference in San Francisco on January 12-14, 2026. The company’s QUELIMMUNE (SCD-PED) therapy for life-threatening acute kidney injury in pediatric patients wa...
01-06 13:53
SeaStar Medical Holding shares are trading lower after the company announced a 1-for-10 reverse split.
SeaStar Medical Holding shares are trading lower after the company announced a ...
2025-12-24 05:26
SeaStar Medical Holding Announces 1-For-10 Reverse Stock Split, Effective January 5, 2026
SeaStar Medical Holding Corporation (NASDAQ: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today theSeaStar Medical Holding Corporation (NASDAQ:ICU),
2025-12-24 05:26
What's Going On With Shares Of SeaStar Medical Today?
Shares of SeaStar Medical Holding Corporation (NASDAQ: ICU) are trading lower Friday after the company initiated a reverse stock split.
2025-12-20 02:11
Why Oracle Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of Oracle Corp (NYSE:ORCL) rose sharply in pre-market trading. TikTok ha...
2025-12-19 17:52
SeaStar Medical shares are trading higher after the FDA approved a reduction in the mandatory enrollment size of its SAVE surveillance registry evaluating Quelimmune safety in pediatric AKI.
SeaStar Medical shares are trading higher after the FDA approved a reduction in...
2025-12-02 21:28
SeaStar Medical Appoints Michael Messinger CFO
SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today
2025-11-17 21:45
电话会总结 ｜ SeaStar Medical(ICU)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据SeaStar Medical业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025财年第三季度净营收为18.3万美元，来自Quellimmune治疗产品销售，相比2024年同期的6.8万美元实现显著增长。截至9月30日的六个月营收较前六个月增长45%。 **盈利能力：** 毛利率达到92%，这是首个完整季度的产品销售成本核算，体现了品牌药物的典型经济特征。 **运营支出：** 2025财年第三季度运营费用为370万美元，较2024年同期的450万美元下降，主要由于咨询费用和人员成本降低，但部分被研发费用和审计费
2025-11-14 12:53
